中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
30期
163-164
,共2页
米氮平%帕罗西汀%抑郁症
米氮平%帕囉西汀%抑鬱癥
미담평%파라서정%억욱증
Mirtazapine%Paroxetine%Depression
目的:对照研究米氮平与帕罗西汀治疗抑郁症的临床治疗效果和不良反应。方法选择2013年3月~2015年2月在我院门诊治疗的70例抑郁症患者作为研究对象。随机把70例患者分成对照组与观察组,每组各35例患者。对照组应用帕罗西汀治疗,观察组应用米氮平治疗,比较第1周末、第8周末两组患者的临床治疗效果和不良反应。结果根据HAMD量表与HAMA量表评分及减分率对两组患者临床治疗效果进行评定,第1周末,观察组治疗效果优于对照组,不良反应少于对照组(P<0.05);第8周末,观察组总有效率与对照组相比无明显差异(P>0.05)。结论米氮平治疗抑郁症与帕罗西汀临床疗效相当,但米氮平比帕罗西汀起效快,而且临床不良反应较少。
目的:對照研究米氮平與帕囉西汀治療抑鬱癥的臨床治療效果和不良反應。方法選擇2013年3月~2015年2月在我院門診治療的70例抑鬱癥患者作為研究對象。隨機把70例患者分成對照組與觀察組,每組各35例患者。對照組應用帕囉西汀治療,觀察組應用米氮平治療,比較第1週末、第8週末兩組患者的臨床治療效果和不良反應。結果根據HAMD量錶與HAMA量錶評分及減分率對兩組患者臨床治療效果進行評定,第1週末,觀察組治療效果優于對照組,不良反應少于對照組(P<0.05);第8週末,觀察組總有效率與對照組相比無明顯差異(P>0.05)。結論米氮平治療抑鬱癥與帕囉西汀臨床療效相噹,但米氮平比帕囉西汀起效快,而且臨床不良反應較少。
목적:대조연구미담평여파라서정치료억욱증적림상치료효과화불량반응。방법선택2013년3월~2015년2월재아원문진치료적70례억욱증환자작위연구대상。수궤파70례환자분성대조조여관찰조,매조각35례환자。대조조응용파라서정치료,관찰조응용미담평치료,비교제1주말、제8주말량조환자적림상치료효과화불량반응。결과근거HAMD량표여HAMA량표평분급감분솔대량조환자림상치료효과진행평정,제1주말,관찰조치료효과우우대조조,불량반응소우대조조(P<0.05);제8주말,관찰조총유효솔여대조조상비무명현차이(P>0.05)。결론미담평치료억욱증여파라서정림상료효상당,단미담평비파라서정기효쾌,이차림상불량반응교소。
Objective A comparative study efifcacy and adverse reactions of mirtazapine and paroxetine in the treatment of depression.Methods 70 patients with depression as the research object from March 2013 to February 2015, in our hospital outpatient department. They were randomly divided into a control group and the observation group, 35 patients in each group. Application of paroxetine treatment group, observation group mirtazapine treatment, the end of first week and the end of eighth week, compare two groups of clinical curative effect and adverse reaction of patients.Results According to HAMD scale and HAMA scale to assess the clinical therapeutic effect in both groups, the end of ifrst week, the treatment effect of observation group was obviously better than the control group, the adverse reaction is less than the control group (P<0.05), the end of eighth week, the treatment effect of observation group compared with the control group were no signiifcant difference (P>0.05).ConclusionMirtazapine is equivalent to paro cefoxitin clinical efficacy for treatment of depression, but mirtazapine is faster than paroxetine effect, and less clinical adverse reaction.